Nyxoah publishes DREAM study data in Journal of Clinical Sleep Medicine

Nyxoah (NYXH) announced that data from its DREAM pivotal study was published online in the Journal of Clinical Sleep Medicine. The DREAM pivotal study presents 12-month safety and efficacy results that supported the Company’s PMA submission to the FDA. The peer-reviewed publication provides detailed analysis of the Genio system’s performance across multiple clinical endpoints. The publication reveals new data on device usage and patient satisfaction that was not included in the Company’s previous announcements. These additional findings show that nightly device usage was greater than 4 hours in more than 70% of nights in 84.3% of participants completing diary entries in the three months preceding the 12-month visit. Overall, the device was used over 70% of the nights by 85.9% of the participants. The publication also reports 90% of patients expressed satisfaction with the therapy. Additionally, data shows that a patient’s snoring score was reduced from 83.5% at baseline to 30.4% at 12 months.